What is the Quality of Evidence (GRADE) for the Risk Difference between Beta-blocker and Placebo for patients with Chronic Heart Failure and chronic kidney disease (CKD) class 3a?
The Quality of Evidence (GRADE) for the Risk Difference between Beta-blocker and Placebo for patients with Chronic Heart Failure and chronic kidney disease (CKD) class 3a is VERY LOW, due to risk of bias, indirectness, and imprecision.